HemaFus RUNX1-RUNX1T1 Fusion Gene Qualitative Detection Kit(PCR-Fluorescent Probing) 

Background

The AML1-ETO gene is one of the most common fusion genes in acute myeloid leukemia (AML). The t(8;21)(q22;q22) chromosomal translocation results at the molecular level in the fusion of AML1 gene (also known as RUNX1) on 21q22 and the ETO gene (also known as RUNA1T1 or MTG8) on 8q22, and its expression product is the AML1-ETO fusion protein (Figure 1). This fusion gene is found in 6%–8% of primary AMLs, 20%–40% of M2, 90% of M2b, rarely in M4 and M1, and very rarely in MDS. AML1-ETO fusion gene can serve as an important basis for molecular typing diagnosis and prognosis observation, and patients with positive AML1-ETO have a better prognosis. AML1-ETO positive leukemia cells have a certain degree of differentiation ability. It can differentiate into mature neutrophils and eosinophils, with better sensitivity to chemotherapy. They also have a good response to high-dose cytarabine treatment, which leads to a high remission rate and disease-free survival rate. The fusion of fusion genes is shown in Figure 2.

图1

Features

Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.

Detection Process

In this method, RNA is isolated and purified from leukocytes in peripheral blood or bone marrow samples, and cDNA is obtained by reverse transcription to quantitatively detect the RUNX1-RUNX1T1 fusion gene by fluorescence quantitative PCR.

Applicable instrument

ABI fluorescence quantitative PCR system (ABI7500, ABI ViiA7)

Ordering Information